Resource Summary Report

Generated by dkNET on Sep 1, 2026

MC-26

RRID:CVCL_0240
Type: Cell Line

Proper Citation

RCB Cat# RCB2657, RRID:CVCL_0240

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0240

Proper Citation: RCB Cat# RCB2657, RRID:CVCL_0240

Description: Cell line MC-26 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse colon adenocarcinoma

Defining Citation: PMID:1149045

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: MC-26

Synonyms: MC26, Colon 26, Colon-26, Colon26, C-26, C26

Cross References: BTO:BTO_0004013, CLO:CLO_0051596, MCCL:MCC:0000130, ChEMBL-Cells:CHEMBL3307623, ChEMBL-Targets:CHEMBL614466, CLS:400156, NCI-DTP:Colon 26, PubChem_Cell_line:CVCL_0240, RCB:RCB2657, TKG:TKG 0518, Wikidata:Q54904167

ID: CVCL_0240

Vendor: RCB

Catalog Number: RCB2657

Record Creation Time: 20220427T220749+0000

Record Last Update: 20260829T234549+0000

Ratings and Alerts

No rating or validation information has been found for MC-26.

No alerts have been found for MC-26.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Kudo-Saito C, et al. (2026) ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer. Cancer research communications, 6(2), 350.

Yamauchi T, et al. (2026) Valine availability controls oncogenic cell-cycle progression through translation of D-type cyclins. Biochemical pharmacology, 246, 117706.

Bae SE, et al. (2026) Macrophage-Myocyte Cross Talk Induces M1 Polarization and Inflammatory Cytokine Production During Cancer Cachexia. Mediators of inflammation, 2026(1), e6461737.

Zhang X, et al. (2025) Arachidonic acid triggers spermidine synthase secretion from primary tumor to induce skeletal muscle weakness upon irradiation. Cell metabolism, 37(8), 1766.

Yoshida Y, et al. (2025) Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense. Theranostics, 15(2), 340.

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R?? strengthens T cell-mediated anti-tumor therapies. Cell reports. Medicine, 5(10), 101747.

Nagira Y, et al. (2023) S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. Molecular cancer therapeutics, 22(9), 1063.

Asano H, et al. (2023) Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(24), 5173.

Harimoto T, et al. (2022) A rapid screening platform to coculture bacteria within tumor spheroids. Nature protocols, 17(10), 2216.

Kim HG, et al. (2022) Metastatic or xenograft colorectal cancer models induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting in a tumor-type-dependent manner. Journal of applied physiology (Bethesda, Md. : 1985), 133(6), 1273.

Chen CY, et al. (2021) Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8+ T Cells. Cancer immunology research, 9(10), 1214.

Madi A, et al. (2020) Regulation of immune cell metabolism by cancer cell oncogenic mutations. International journal of cancer, 147(2), 307.

Judge SM, et al. (2020) MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer. Cancer research, 80(9), 1861.

Chen CY, et al. (2019) Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice. Journal for immunotherapy of cancer, 7(1), 21.